Former Connecticut biotech executive Dr. Manon Cox will take the post of CEO at Seattle’s AVM Biotechnology, the company announced Tuesday.
A current member of AVM’s board of directors, Cox will assume the top job as part of a new leadership team at the startup, which is developing drugs to treat Non-Hodgkin’s Lymphoma. A first clinical trial of the company’s AVM0703-001 is currently enrolling patients.
“I am very excited to play a larger role in building this organization and leading the development and product approval of AVM0703,” Cox said. “I look forward to guiding the team in accomplishing this mission.”
As president and CEO of Meriden-based Protein Sciences, Cox helped broker the company’s $750 million sale to Sanofi in 2017. She left the company in January of 2018.
Cox joined Protein Sciences in 1998 as director of business development and helped the company launch FluBlok, the first recombinant influenza vaccine on the market.
